Objective: The objective of this study was to evaluate the frequency of head benign and malignant lesions with regard to age group, sex, site and type of lesion and clinical variety in a tertiary care hospital in Lahore. Methodology: Basic research design: An observational cross-sectional study, included collection and analysis of histopathological data over the last 4 years i.e. 2016-2019. Test of significance chi-square was done for data analysis in IBM SPSS v17. Clinical setting: Pathology Departments of Sheikh Zayed Hospital (tertiary care hospital). Results: Sample included a total of 952 patient records in this study, with 587 (61.7%) males and 365 (38.3%) females. There were 514 cases of the head region and 438 cases of the neck region. Out of 514 total head region cases, 66 were malignant and 458 were benign. Participants were divided into age groups (1-18, 19-35, 36-50, 51-70, 70+) years respectively. The prevalence of benign cancers in head region was calculated in percentages according to which most patients were of nasal polyp at 26.3%, pleomorphic adenoma were 3.4%, with fibro-epithelial polyp were 9.5%. In the malignant category though Squamous cell carcinoma (SCC) was the most prevalent malignant lesion with highest frequency recorded in tongue region were 4.0%, rest with SCC nose were 0.6%, with SCC soft palate were 2.1%. The results of the chi-square revealed that there was a significant difference found with regards to the prevalence of various benign lesions in the head region between males (X2 = 1003.041, P>.001) and females (X2 = 593.937, P>.001). In addition, the difference among males and females was found statistically significant with regards to the prevalence of different types of malignant tumors in head region (for males, X2 = 238.447, P>.001, for females, X2 = 112.641, P>.001). With regards to the age groups the prevalence of different types of benign cancers was found to be statistically significant at head region (X2 = 140.500, P>.001), however there was a non-significant difference between the age-wise prevalence of different types of malignant cancers of head region (X2 = 44.702, P = .281). Conclusion: A reappraisal of neoplastic lesions of this important anatomical region in this study highlight the wide spectrum of tumors encountered along with its relative frequency. Squamous cell carcinoma constitutes the highest percentage of all the malignancies in the head region. Though head malignancies are a serious concern, good awareness, education, and early diagnosis can reduce their incidence.
Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 toMar 2017. Methodology: A total of 182 consecutive patients with age ≥18 years and positive HCV RNA by polymerasechain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet countof <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes wereexcluded from study. Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients withgenotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients withdual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naïve and100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was83.3% (p=0.331) and 88.9% in treatment naïve and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia. Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of sideeffects, genotype 3 being the most predominant genotype.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.